Form PRE 14A - Other preliminary proxy statements:
SEC Accession No. 0001493152-25-018343
Filing Date
2025-10-16
Accepted
2025-10-16 17:25:39
Documents
17
Period of Report
2025-10-16

Document Format Files

Seq Description Document Type Size
1 PRE 14A formpre14a.htm   iXBRL PRE 14A 927302
2 GRAPHIC proxy_001.jpg GRAPHIC 440504
3 GRAPHIC proxy_002.jpg GRAPHIC 279146
  Complete submission text file 0001493152-25-018343.txt   3447105

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE lixt-20241231.xsd EX-101.SCH 6111
5 XBRL DEFINITION FILE lixt-20241231_def.xml EX-101.DEF 11006
6 XBRL LABEL FILE lixt-20241231_lab.xml EX-101.LAB 66747
7 XBRL PRESENTATION FILE lixt-20241231_pre.xml EX-101.PRE 46078
19 EXTRACTED XBRL INSTANCE DOCUMENT formpre14a_htm.xml XML 118591
Mailing Address 433 PLAZA REAL SUITE 275 BOCA RATON FL 33432
Business Address 433 PLAZA REAL SUITE 275 BOCA RATON FL 33432 310 203 2902
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Filer) CIK: 0001335105 (see all company filings)

EIN.: 202903526 | State of Incorp.: DE | Fiscal Year End: 1231
Type: PRE 14A | Act: 34 | File No.: 001-39717 | Film No.: 251398442
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)